同步放化疗治疗Ⅲ期非小细胞肺癌的效果  

Chemoradiotherapy for Stage Ⅲ Non-small Cell Lung Cancer

作　　者：刘华[1] 戴伟杰[1] 徐丽娟[1] 宋亚颀[1] 陈小飞[1] 

机构地区：[1]江苏省淮安市第一人民医院,223300

出　　处：《实用癌症杂志》2015年第12期1843-1845,共3页The Practical Journal of Cancer

摘　　要：目的探讨Ⅲ期非小细胞肺癌患者采用同步放化疗治疗的临床疗效。方法按照随机抛硬币法将74例Ⅲ期非小细胞肺癌患者分组为对照组（序贯放化疗）与观察组（同步放化疗）,分别为37例。随访6-60个月,平均为（42.6±9.4）个月。统计2组患者临床疗效、生存时间及治疗期间所产生的不良反应。结果经治疗及随访发现,观察组临床治疗有效率为67.57%,明显高于对照组的48.65%（P〈0.05）;观察组平均生存时间为（19.9±4.1）个月,明显长于对照组（12.5±3.4）个月,P〈0.05。2组主要不良反应为消化道反应和骨髓抑制及放射性食管炎,但2组不良反应率比较,差异无统计学意义（P〉0.05）。结论应用同步放化疗治疗Ⅲ期非小细胞肺癌疗效显著且安全。Objective To explore the clinical efficacy of chemoradiotherapy for stage Ⅲ non-small cell lung cancer. Methods According to the method of random flip a coin,74 cases of stageⅢnon-small cell lung cancer patients were divided into the control group （ sequential chemoradiotherapy） and the observation group （ chemoradiotherapy） ,37 cases in each.Follow up was 6 -60 months,the average follow up was （42.6 ±9.4） months.Clinical curative effect,survival time and adverse reac-tions of the 2 groups of patients were recorded.Results After treatment and follow-up, effective rate in the observation group （67.57%） was significantly higher than of the control group（48.65%）,P〈0.05;the average survival time in the observation group was （19.9 ±4.1） months,which was significantly longer than that of the control group （12.5 ±3.4） months,P〈0.05. The main adverse reactions were gastrointestinal reactions,bone marrow suppression and radiation esophagitis,but adverse reaction rates between the 2 groups had no significant difference,P〉0.05.Conclusion Chemoradiotherapy for stage Ⅲ non-small cell lung cancer is effective and safe.

关 键 词：Ⅲ期非小细胞肺癌 同步放化疗 生存期 序贯放化疗 

分 类 号：R734.2[医药卫生—肿瘤]